Compare ARDX & LYTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | LYTS |
|---|---|---|
| Founded | 2007 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building Products |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.3M | 912.7M |
| IPO Year | 2014 | 1994 |
| Metric | ARDX | LYTS |
|---|---|---|
| Price | $3.24 | $20.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | $12.90 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 4.1M | 354.8K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 0.97% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.67 |
| Revenue | $2,607,000.00 | ★ $573,377,000.00 |
| Revenue This Year | $19.98 | $28.38 |
| Revenue Next Year | $27.70 | $7.65 |
| P/E Ratio | ★ N/A | $30.81 |
| Revenue Growth | N/A | ★ 22.09 |
| 52 Week Low | $3.18 | $17.21 |
| 52 Week High | $8.40 | $27.36 |
| Indicator | ARDX | LYTS |
|---|---|---|
| Relative Strength Index (RSI) | 29.24 | 48.41 |
| Support Level | N/A | $18.38 |
| Resistance Level | $3.63 | $21.22 |
| Average True Range (ATR) | 0.11 | 0.58 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 12.50 | 51.59 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Display solutions segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets, including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells, and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays, and custom display elements.